Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | MITF | O75030 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | SNCA | P37840 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.64 |
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415708 | 1.00 | PTPN1 (0.76) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL20284430 | 0.95 | PTPN1 (0.86) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL10684470 | 0.92 | PTPN1 (0.88) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL8420639 | 0.90 | DEGS1 (0.75) | PTPN1MEN1KMT2APOLBTDP1 | |
| SCHEMBL900928 | 0.90 | DEGS1 (0.75) | PTPN1MEN1KMT2APOLBTDP1 | |
| SCHEMBL899585 | 0.90 | DEGS1 (0.75) | PTPN1MEN1KMT2APOLBTDP1 | |
| SCHEMBL8768807 | 0.86 | MEN1 (0.86) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL8770854 | 0.86 | PTPN1 (0.79) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL18938397 | 0.86 | NPC1 (0.77) | PTPN1MITFMEN1KMT2APOLB | |
| SCHEMBL3639776 | 0.85 | MITF (1.00) | PTPN1MITFMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101230033-B | New azabicycloalkane derivatives, preparing method and medicament combination containing the same | SERVIER LAB | 2011-03-09 | — | — | CN | disclosed |
| CN-100577160-C | Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same | SERVIER LAB | 2010-01-06 | — | — | CN | disclosed |
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| CN-101230033-A | New azabicycloalkane derivatives, preparing method and medicament combination containing the same | SERVIER LAB (FR) | 2008-07-30 | — | — | CN | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
| CN-1921848-A | Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720544-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0471811-A4 | ALLOSTERIC HEMOGLOBIN MODIFIERS | — | 1992-11-25 | — | — | EP | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0471811-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS. | INNOVATIVE TECH CENTER (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5049695-A | Substituted diphenyl carbamates | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991012235-A1 | ALLOSTERIC HEMOGLOBIN MODIFIERS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | PTPN1 990/4885MITF 2554/4885MEN1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.